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recommended high volumes of fluid administration, and
have recommended fluid restriction for diseases where
fluid overload could develop.
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Active vitamin D agents
and refractory
hyperparathyroidism in
dialysis patients
To the Editor: In the March 2005 issue of Kidney Inter-
national, Nakanishi et al [1] presented a very interesting
study showing that only serum levels of fibroblast growth
factor-23 (FGF-23) were significantly related to the prog-
nosis of parathyroid function in dialysis patients. The fac-
tors they included in their stepwise regression analysis
were serum FGF-23, calcium, phosphate, intact PTH, in-
tact osteocalcin, bone-specific alkaline phosphatase lev-
els, age, and dialysis vintage [1]. They did not include
treatment with active vitamin D agents, even though
the pretreatment serum FGF-23 levels were significantly
higher in those patients (47 out of 103) who were receiv-
ing vitamin D. A very recent paper by Foley et al [2]
showed that parathyroidectomy was associated, among
other factors, also with the previous use of IV vitamin D
(hazards ratio 2.44, P < 0.0001). Furthermore, we showed
that nodular hyperplasia of parathyroid glands was signif-
icantly associated with IV calcitriol pulse therapy (CPT)
in hemodialysis patients [3]. The simplest explanation for
the paradoxic association between this histologic pattern
and IV CPT could be that CPT is often attempted as
a “final” nonsurgical strategy when parathyroidectomy
is being considered [2]. On the contrary, we hypothe-
sized that, paradoxically, long-term IV CPT might be
among the factors determining nodular hyperplasia: in
fact, a disturbed and/or decreased action of long-term
IV CPT at the level of the parathyroid cell might cause
progression into the cell cycle and a disinhibition of c-
myc expression, leading to a more aggressive nodular
type proliferation of parathyroid glands [4]. Therefore,
we kindly ask Nakanishi et al to reanalyze their data, in-
cluding vitamin D treatment in their stepwise regression
analysis.
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Reply from the Authors
Thank you for your interest in our recent paper [1].
We agree with you that the cumulative dosage of active
vitamin D therapy may correlate with the severity of sec-
ondary hyperparathyroidism. However, we believe that
the more intensive vitamin D therapy should be the con-
sequence, but not the cause, of the nodular transforma-
tion of parathyroid cells, since such cells displayed less
sensitivity to vitamin D [2].
We have reported that the use of active vitamin D
agents may be related to the increased serum FGF-23 lev-
els in dialysis patients [1, 3, 4]. Therefore, we needed to
avoid applying FGF-23 and active vitamin D therapy to-
gether as independent variables when performing a step-
wise regression analysis. Although it may be possible to
perform a stepwise analysis applying active vitamin D
therapy instead of FGF-23, it must be “active vitamin D
therapy throughout the observation period,” but not “ac-
tive vitamin D therapy at the beginning of the observation
period.”
Furthermore, the physicians in charge changed treat-
ment strategy depending upon the plasma intact PTH
levels in our study. Accordingly, “active vitamin D ther-
apy throughout the observation period” was obviously a
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variable dependent on PTH levels. Thus, it seems statis-
tically inappropriate to apply this factor as independent
variables in the stepwise regression assay to detect “the
patients with high plasma intact PTH levels.”
Taken together, we regret to conclude that we could not
perform the stepwise analyses including active vitamin D
treatment as an independent variable in this study. We
hope your attractive hypothesis will be proved in some
other opportunities.
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Combination of intravenous
iron sucrose and ascorbic acid
in hemodialysis patients
To the Editor: We read with great interest the recent
article by Sturm et al [1] demonstrating ascorbic acid
together with iron sucrose can increase the intracellu-
lar labile iron pool and iron mobilization to transferrin
in human hepatoma HepG2 cells. The authors reported
that neither ferric gluconate nor iron dextran has such
an effect. The extrapolation of this important finding to
clinical practice, as it was noted in the manuscript, led to
the conclusion that iron sucrose could be a more benefi-
cial iron preparation for further response to recombinant
human erythropoietin (rHuEPO) with adjuvant ascorbic
acid replacement. As it was cited in the paper, the studies
investigating the role of ascorbic acid as an adjuvant ther-
apy to rHuEPO enrolled the hemodialysis patients with
iron overload. Most of the studies on this issue excluded
the patients on iron replacement due to iron overload [2,
3] and reported a beneficial effect of ascorbic acid only
in patients with functional iron deficiency. The effect of
concomitant use of ascorbic acid with intravenous iron on
rHuEPO response has not been extensively evaluated.
However, in our recent randomized crossover study, we
investigated this issue in all hemodialysis patients, includ-
ing patients with normal iron status, as well. All patients
were on maintenance intravenous iron sucrose and were
administrated 500 mg ascorbic acid 3 times a week for 6
months. We found that supplementation of ascorbic acid
resulted in a significant increase in hemoglobin levels to-
gether with a significant increase in transferrin saturation
in approximately 65% of the patients [4]. Therefore, iron
sucrose and ascorbic acid can be a better combination
due to increasing the amount of bioavailable iron from
iron sucrose. However, we recommend further clinical
studies to evaluate the effect of other intravenous iron
preparations in combination with ascorbic acid.
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Continuous renal replacement
therapy in the critically ill
patient
To the Editor: I read with interest the discussion of
Dr. Mehta [1]. As “positive” findings, I see the follow-
ing: (1) The treatment protocol is adapted to the widely
available Prisma machine. Nevertheless, in the future I
hope to see more versatile models permitting the use of
other than Hospal filters, Hospal “sets,” and more flexible
pump functions; (2) the recipe for citrate local anticoagu-
lation, which reduces side effects in patients und prolongs
filter function; (3) the great idea of partial predilution
